Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) FCF Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed FCF Margin for 16 consecutive years, with 13.03% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 3275.0% to 13.03% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 3.87% through Dec 2025, up 581.0% year-over-year, with the annual reading at 3.87% for FY2025, 581.0% up from the prior year.
  • FCF Margin for Q4 2025 was 13.03% at Anika Therapeutics, down from 17.91% in the prior quarter.
  • The five-year high for FCF Margin was 34.2% in Q3 2024, with the low at 221.11% in Q4 2023.
  • Average FCF Margin over 5 years is 11.13%, with a median of 4.22% recorded in 2025.
  • The sharpest move saw FCF Margin crashed -20385bps in 2023, then skyrocketed 20139bps in 2024.
  • Over 5 years, FCF Margin stood at 13.06% in 2021, then plummeted by -232bps to 17.26% in 2022, then crashed by -1181bps to 221.11% in 2023, then surged by 91bps to 19.72% in 2024, then skyrocketed by 166bps to 13.03% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 13.03%, 17.91%, and 5.87% for Q4 2025, Q3 2025, and Q2 2025 respectively.